13-[(4-tert-butylphenyl)methyl]-7,19-difluoro-3-[(2R,3R,4S,5S,6S)-6-(fluoromethyl)-3,4,5-trihydroxyoxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione | 406722-15-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 13-[(4-tert-butylphenyl)methyl]-7,19-difluoro-3-[(2R,3R,4S,5S,6S)-6-(fluoromethyl)-3,4,5-trihydroxyoxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione
• CAS: 406722-15-4
• 化学式: C₃₇H₃₂F₃N₃O₆
• 分子量: 671.673
• InChiKey: BDPCQHVDHIUFHF-OFWRJWMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  49
• 可旋转键数：
  5
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  128
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  13-[(4-tert-butylphenyl)methyl]-7,19-difluoro-3-[(2R,3R,4S,5S,6S)-6-(fluoromethyl)-3,4,5-trihydroxyoxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 3,8-Difluoro-11-((2R,3R,4S,5S,6S)-6-fluoromethyl-3,4,5-trihydroxy-tetrahydro-pyran-2-yl)-11,12-dihydro-11,12-diaza-indeno[2,1-a]fluorene-5,6-dicarboxylic acid
  参考文献：
  名称：

  Discovery of a Fluoroindolo[2,3-a]carbazole Clinical Candidate with Broad Spectrum Antitumor Activity in Preclinical Tumor Models Superior to the Marketed Oncology Drug, CPT-11

  摘要：

  A series of fluoroglycosylated fluoroindolocarbazoles was examined with respect to their topoisomerase I activity, cytotoxicity, and selectivity. The lead clinical candidate from this series, BMS-250749, displays broad spectrum antitumor activity superior to CPT-11 against some preclinical xenograft models, including curative antitumor activity against Lewis lung carcinoma.

  DOI：

  10.1021/jm049090z
• 作为产物：
  描述：

  13-[(4-Tert-butylphenyl)methyl]-7,19-difluoro-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione 在 palladium dihydroxide 偶氮二甲酸二异丙酯 、 三苯基膦 、 环己烯 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 13-[(4-tert-butylphenyl)methyl]-7,19-difluoro-3-[(2R,3R,4S,5S,6S)-6-(fluoromethyl)-3,4,5-trihydroxyoxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione
  参考文献：
  名称：

  Discovery of a Fluoroindolo[2,3-a]carbazole Clinical Candidate with Broad Spectrum Antitumor Activity in Preclinical Tumor Models Superior to the Marketed Oncology Drug, CPT-11

  摘要：

  A series of fluoroglycosylated fluoroindolocarbazoles was examined with respect to their topoisomerase I activity, cytotoxicity, and selectivity. The lead clinical candidate from this series, BMS-250749, displays broad spectrum antitumor activity superior to CPT-11 against some preclinical xenograft models, including curative antitumor activity against Lewis lung carcinoma.

  DOI：

  10.1021/jm049090z